Announcement PDF RNS Number : 0116F Genedrive PLC 28 October 2025 genedrive plc ("genedrive" or the "Company") Memorandum of Understanding with Kingdom of Saudi Arabia Ministry of Health to introduce the Genedrive® MT-RNR1 ID Kit under Generations Hear programme genedrive plc (LSE: GDR), the point of care pharmacogenetic testing company, announces that genedrive's exclusive distribution partner in the Kingdom of Saudi Arabia ("KSA"), iDeal iDea for Medical Equipment Technology has signed a Memorandum of Understanding ("MOU") with the KSA Ministry of Health ("MOH"). The MOU scope is to pilot the Genedrive® MT-RNR1 ID Kit for potential national implementation under a national initiative "Generations Hear". The MOU was signed by Hatim Najjar, Founder and CEO of iDeal iDea, Dr Abdullah Al-Sohimi, General Director of Specialized Centers at Ministry of Health, and Dr Salem Baharoon, Deputy Minister for Therapeutic Services, Ministry of Health. This initiative aligns with the Saudi Vision 2030, supporting the national objective of advancing precision medicine, enhancing quality of life, and transforming healthcare from reactive treatment to proactive prevention, from disease management to preventive care, and from pain to hope. Dr Gino Miele, CEO of genedrive plc, said: "We are delighted with the signing of this MOU, which builds further on our commercial traction in Saudi Arabia and aligns perfectly to the long-term Saudi health goals. We are grateful to our valued partners at iDeal iDea for their support and look forward to progressing through pilot phase with the goal of implementation at national level." Hatim Najjar, Founder and CEO of iDeal iDea for Medical Equipment Technology, said: "The Generations Hear initiative embodies Saudi Arabia's true transformation in the healthcare sector, leveraging genetic innovation to safeguard the health and lives of future generations. At iDeal iDea for Medical Equipment Technology, we are proud to provide innovative medical solutions in line with Saudi Vision 2030 and the Health Transformation Program, through national partnerships that advance precision medicine and strengthen preventive healthcare." For further details please contact: genedrive plc +44 (0)161 989 0245 Gino Miele: CEO / Russ Shaw: CFO Peel Hunt LLP (Nominated Adviser and Broker) +44 (0)20 7418 8900 James Steel Walbrook PR Ltd (Media & Investor Relations) +44 (0)20 7933 8780 or genedrive@walbrookpr.com Anna Dunphy +44 (0)7876 741 001 About genedrive plc (http://www.genedrive.com) genedrive plc is a pharmacogenetic testing company developing and commercialising a low cost, rapid, versatile and simple to use point of need pharmacogenetic platform for the diagnosis of genetic variants. This helps clinicians to quickly access key genetic information that will aid them make the right choices over the right medicine or dosage to use for an effective treatment, particularly important in time-critical emergency care healthcare paradigms. Based in the UK, the Company is at the forefront of Point of Care pharmacogenetic testing in emergency healthcare. Pharmacogenetics informs on how your individual genetics impact a medicines ability to work for you. Therefore, by using pharmacogenetics, medicine choices can be personalised, made safer and more effective. The Company has launched its two flagship products, the Genedrive® MT-RNR1 ID Kit and the Genedrive® CYP2C19 ID Kit, both developed and validated in collaboration with NHS partners and deployed on its point of care thermocycler platform. Both tests are single-use disposable cartridges which are ambient temperature stable, circumventing the requirement for cold chain logistics. The Directors believe the Genedrive® MT-RNR1 ID Kit is a worlds-first and allows clinicians to make a decision on antibiotic use in neonatal intensive care units within 26 minutes, ensuring vital care is delivered, avoiding adverse effects potentially otherwise encountered and with no negative impact on the patient care pathway. Its CYP2C19 ID Kit which has no comparably positioned competitor currently allows clinicians to make a decision on the use of Clopidogrel in stroke patients in 70 minutes, ensuring that patients who are unlikely to benefit from or suffer adverse effects from Clopidogrel receive an alternative antiplatelet therapeutic in a timely manner, ultimately improving outcomes. Both tests have undergone review by the National Institute for Health and Care Clinical Excellence ("NICE") and have been recommended for use in the UK NHS. The Company has a clear commercial strategy focused on accelerating growth through maximising in-market sales, geographic and portfolio expansion and strategic M&A, and operates out of its facilities in Manchester. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com. RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy. END MSCUBAWRVOURUAA